Published in Mol Cell Biol on February 01, 2003
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol (2008) 5.02
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol (2011) 4.63
Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol (2011) 3.51
Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol (2006) 3.15
A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci U S A (2005) 2.50
Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A (2007) 2.31
The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J (2005) 2.15
TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem (2009) 1.96
Development of the endochondral skeleton. Cold Spring Harb Perspect Biol (2013) 1.89
TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol (2007) 1.86
The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem (2008) 1.67
Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci (2007) 1.61
Runx2 regulates G protein-coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem (2008) 1.32
Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. Mol Cell Biol (2009) 1.25
Glis3 is associated with primary cilia and Wwtr1/TAZ and implicated in polycystic kidney disease. Mol Cell Biol (2009) 1.18
TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (2012) 1.15
Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr (2009) 1.11
Signal transduction and transcriptional regulation during mesenchymal cell differentiation. J Bone Miner Metab (2008) 1.10
Resolving the Two "Bony" Faces of PPAR-gamma. PPAR Res (2006) 1.09
Role of substratum stiffness in modulating genes associated with extracellular matrix and mechanotransducers YAP and TAZ. Invest Ophthalmol Vis Sci (2013) 0.98
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol (2015) 0.95
MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. Cell Death Dis (2015) 0.94
Determination of the differentiation capacities of murines' primary mononucleated cells and MC3T3-E1 cells. Cancer Cell Int (2010) 0.90
Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-β. Oncotarget (2015) 0.90
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol (2015) 0.88
Regulation and function of the TAZ transcription co-activator. Int J Biochem Mol Biol (2011) 0.87
Identification of novel Pax8 targets in FRTL-5 thyroid cells by gene silencing and expression microarray analysis. PLoS One (2011) 0.87
Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model. Mol Cell Biol (2014) 0.84
TAZ suppresses NFAT5 activity through tyrosine phosphorylation. Mol Cell Biol (2012) 0.83
Osteoblast-targeted overexpression of TAZ increases bone mass in vivo. PLoS One (2013) 0.82
Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction. Diagn Pathol (2014) 0.81
Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol (2014) 0.81
Intracellular delivery of cell-penetrating peptide-transcriptional factor fusion protein and its role in selective osteogenesis. Int J Nanomedicine (2014) 0.80
Novel TAZ modulators enhance myogenic differentiation and muscle regeneration. Br J Pharmacol (2014) 0.79
RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells. Oncotarget (2015) 0.77
The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway. Oncotarget (2016) 0.77
Polarized and Stage-Dependent Distribution of Immunoreactivity for Novel PDZ-Binding Protein Preso1 in Adult Neurogenic Regions. Endocrinol Metab (Seoul) (2014) 0.76
Physiological mechanisms and therapeutic potential of bone mechanosensing. Rev Endocr Metab Disord (2015) 0.76
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. J Exp Clin Cancer Res (2016) 0.76
Disease implication of hyper-Hippo signalling. Open Biol (2016) 0.75
Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis. Gastroenterology (2016) 0.75
WW Domain Containing Transcription Regulator regulates human conjunctiva epithelial cell proliferation via inhibiting TGFβ signaling pathway [corrected]. Mol Vis (2012) 0.75
Co-culture with periodontal ligament stem cells enhances osteogenic gene expression in de-differentiated fat cells. Hum Cell (2014) 0.75
Regulation of TAZ in cancer. Protein Cell (2016) 0.75
Transcriptional coactivator with PDZ-binding motif is required to sustain testicular function on aging. Aging Cell (2017) 0.75
Transcriptional co-activator with PDZ-binding motif overexpression promotes cell proliferation and transcriptional co-activator with PDZ-binding motif deficiency induces cell cycle arrest in neuroblastoma. Oncol Lett (2017) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell (1997) 13.53
14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol (2000) 6.94
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem (1995) 6.25
NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science (2000) 5.20
A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J (1999) 4.66
TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J (2000) 4.55
Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol (1995) 4.28
A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev (1999) 3.88
Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice. Genes Dev (2001) 3.43
14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell Biol (1996) 2.91
MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem (2000) 2.83
CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J Biol Chem (2001) 2.27
Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem (1997) 2.27
Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfbeta. Mol Cell Biol (1998) 2.13
Cbfa1: a molecular switch in osteoblast biology. Dev Dyn (2000) 1.91
Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem (1999) 1.88
Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus. J Biol Chem (1997) 1.85
The human testis determining factor SRY binds a nuclear factor containing PDZ protein interaction domains. J Biol Chem (1997) 1.46
Bridge-1, a novel PDZ-domain coactivator of E2A-mediated regulation of insulin gene transcription. Mol Cell Biol (1999) 1.38
Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. J Cell Biochem Suppl (1998) 1.32
Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem (1999) 1.11
Bone formation and factors affecting this process. Matrix Biol (2000) 1.05
Transcriptional control of osteoblast differentiation. Biochem Soc Trans (1998) 0.85
Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 10.41
p53 mutant mice that display early ageing-associated phenotypes. Nature (2002) 10.05
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature (2005) 6.43
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol (2002) 6.20
Leptin regulates bone formation via the sympathetic nervous system. Cell (2002) 5.95
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell (2004) 5.80
A twist code determines the onset of osteoblast differentiation. Dev Cell (2004) 5.40
ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell (2004) 5.27
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J (2012) 5.03
Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A (2008) 4.77
SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell (2006) 4.01
The molecular clock mediates leptin-regulated bone formation. Cell (2005) 3.88
WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature (2005) 3.44
Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev (2005) 3.38
A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell (2009) 3.28
Endocrine regulation of male fertility by the skeleton. Cell (2011) 3.20
Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol (2004) 2.90
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol (2012) 2.58
ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab (2006) 2.55
FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest (2009) 2.46
Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med (2010) 2.32
Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum (2006) 2.19
PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development (2002) 2.19
miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol (2012) 2.15
The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol (2008) 2.14
Advancing dental implant surface technology--from micron- to nanotopography. Biomaterials (2008) 2.01
Maternal and offspring pools of osteocalcin influence brain development and functions. Cell (2013) 2.00
Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell (2006) 1.95
Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem (2005) 1.91
p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol (2005) 1.86
An analysis of skeletal development in osteoblast-specific and chondrocyte-specific runt-related transcription factor-2 (Runx2) knockout mice. J Bone Miner Res (2013) 1.85
Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res (2011) 1.84
Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. J Clin Invest (2013) 1.81
Human adipose-derived adult stem cells produce osteoid in vivo. Tissue Eng (2004) 1.77
Essential role of STAT3 in body weight and glucose homeostasis. Mol Cell Biol (2004) 1.74
The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest (2009) 1.73
The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res (2011) 1.70
Osteocalcin promotes β-cell proliferation during development and adulthood through Gprc6a. Diabetes (2013) 1.68
Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med (2002) 1.67
A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol (2009) 1.64
In vivo analysis of Wnt signaling in bone. Endocrinology (2007) 1.61
Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation. J Biol Chem (2001) 1.57
ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J Biol Chem (2004) 1.55
Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics (2004) 1.54
Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest (2003) 1.53
Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab (2008) 1.52
Runx2 inhibits chondrocyte proliferation and hypertrophy through its expression in the perichondrium. Genes Dev (2006) 1.52
Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev (2003) 1.51
Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor. Proc Natl Acad Sci U S A (2012) 1.50
PTH/PTHrP receptor delays chondrocyte hypertrophy via both Runx2-dependent and -independent pathways. Dev Biol (2006) 1.50
Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation. J Cell Biol (2010) 1.49
Survival of short dental implants for treatment of posterior partial edentulism: a systematic review. Int J Oral Maxillofac Implants (2012) 1.46
Proteoglycan desulfation determines the efficiency of chondrocyte autophagy and the extent of FGF signaling during endochondral ossification. Genes Dev (2008) 1.46
Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell (2005) 1.44
MAML1 enhances the transcriptional activity of Runx2 and plays a role in bone development. PLoS Genet (2013) 1.42
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
The role of complete overdentures in esthetic rehabilitation of the adolescent oligodontia patient. A case report. J Esthet Restor Dent (2010) 1.40
Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci U S A (2008) 1.34
Transcription factors in bone: developmental and pathological aspects. Trends Mol Med (2002) 1.30
An ELISA-based method to quantify osteocalcin carboxylation in mice. Biochem Biophys Res Commun (2010) 1.29
Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem (2005) 1.27
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One (2012) 1.25
The effects of implant surface nanoscale features on osteoblast-specific gene expression. Biomaterials (2009) 1.24
The combination of micron and nanotopography by H(2)SO(4)/H(2)O(2) treatment and its effects on osteoblast-specific gene expression of hMSCs. J Biomed Mater Res A (2010) 1.23
Molecular bases of the sympathetic regulation of bone mass. Bone (2008) 1.21
Cell-type-dependent up-regulation of in vitro mineralization after overexpression of the osteoblast-specific transcription factor Runx2/Cbfal. J Bone Miner Res (2002) 1.21
Facial distortion secondary to idiopathic gingival hyperplasia: surgical management and oral reconstruction with endosseous implants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2005) 1.19
Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab (2013) 1.19
Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone. J Biol Chem (2005) 1.19
Regulation of bone formation and vision by LRP5. N Engl J Med (2002) 1.19
Optical imaging of hydroxyapatite in the calcified vasculature of transgenic animals. Arterioscler Thromb Vasc Biol (2006) 1.17
Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med (2011) 1.16
Spatial expression of Cbfa1/Runx2 isoforms in teeth and characterization of binding sites in the DSPP gene. Connect Tissue Res (2002) 1.15
Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol (2006) 1.15
A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. Genes Dev (2013) 1.15
Atf4 regulates chondrocyte proliferation and differentiation during endochondral ossification by activating Ihh transcription. Development (2009) 1.15
Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5). J Biol Chem (2012) 1.14
Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest (2014) 1.13
An Osteoblast-dependent mechanism contributes to the leptin regulation of insulin secretion. Ann N Y Acad Sci (2009) 1.13
Genetic mouse models for bone studies--strengths and limitations. Bone (2011) 1.10
Transforming growth factor β suppresses osteoblast differentiation via the vimentin activating transcription factor 4 (ATF4) axis. J Biol Chem (2012) 1.10
The effect of hydrofluoric acid treatment of TiO2 grit blasted titanium implants on adherent osteoblast gene expression in vitro and in vivo. Biomaterials (2007) 1.10
CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev (2010) 1.09
Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet (2011) 1.06
The two faces of serotonin in bone biology. J Cell Biol (2010) 1.05
Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol Cell Biol (2009) 1.05
Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology (2006) 1.05
Osteopontin upregulation and polymerization by transglutaminase 2 in calcified arteries of Matrix Gla protein-deficient mice. J Histochem Cytochem (2006) 1.04
Prosthetic complications in an implant-retained mandibular overdenture population: initial analysis of a prospective study. J Prosthet Dent (2002) 1.04
Vimentin inhibits ATF4-mediated osteocalcin transcription and osteoblast differentiation. J Biol Chem (2009) 1.02
Gut-derived serotonin is a multifunctional determinant to fasting adaptation. Cell Metab (2012) 1.02
An in vivo model to study osteogenic gene regulation: targeting an avian retroviral receptor (TVA) to bone with the bone sialoprotein (BSP) promoter. J Bone Miner Res (2005) 1.02